

L.N. 13 of 2025

**Dangerous Drugs Ordinance (Amendment of First
Schedule) Order 2025**

(Made by the Chief Executive under section 50(1) of the Dangerous
Drugs Ordinance (Cap. 134) after consultation with the Executive
Council)

1. Commencement

This Order comes into operation on 14 February 2025.

2. Dangerous Drugs Ordinance amended

The Dangerous Drugs Ordinance (Cap. 134) is amended as set
out in section 3.

3. First Schedule amended

(1) First Schedule, Part I, paragraph 1(a)—

- (a) **Repeal item** “ADB-BUTINACA (N-[1-(氨基羰基)-2,2-二甲基丙基]-1-丁基-1H-吡唑-3-甲酰胺)”;
- (b) before item “1-Benzylpiperazine (1-苄基哌嗪)”—

Add

“N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-
1H-indazole-3-carboxamide (N-[1-(氨基羰基)-2,2-
二甲基丙基]-1-丁基-1H-吡唑-3-甲酰胺)”.

(2) First Schedule, Part I, paragraph 1(a), after item
“Bromazepam (溴西泮)”—

Add

“Bromazolam (溴唑仑)”.

- (3) First Schedule, Part I, paragraph 1(a), after item “Brotizolam (溴噻二氮草)” —

Add

“Butonitazene (異丙基依托)”.

- (4) First Schedule, Part I, paragraph 1(a), after item “Etizolam (依替唑侖)” —

Add

“Etomidate (依托咪酯)”.

- (5) First Schedule, Part I, paragraph 1(a), after item “Isomethadone (異美沙酮)” —

Add

“Isopropoxate (異丙帕酯)”.

- (6) First Schedule, Part I, paragraph 1(a), after item “Methyl phenidate (哌醋甲酯)” —

Add

“Metomidate (美托咪酯)”.

- (7) First Schedule, Part I, paragraph 1(a), after item “Propiram (丙吡胺)” —

Add

“Propoxate (丙帕酯)”.

Eric CHAN Kwok-ki
Acting Chief Executive

11 February 2025

Explanatory Note

This Order amends Part I of the First Schedule to the Dangerous Drugs Ordinance (Cap. 134) to—

- (a) bring 6 substances into the regulatory regime under the Ordinance; and
- (b) make a technical amendment to the name of one of the substances specified in paragraph 1(a) of that Part.